Carla Boccaccio

Metis Precision Medicine is a B-Corp founded with the vision of bringing powerful cancer therapies to patients in need. Metis owns the intellectual property of a suite of anti-Met monoclonal antibodies (mAbs), with different and unique mechanisms of action, and is currently seeking investors, biotech or pharmaceutical companies interested inacquiring the relevant platform technology on a global basis.